RxDoctor Payments Data

Brett Rankin, MD

Otolaryngology · Kittery, MENPI 1831296748

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 44.4% of the total. Reporting peaked in 2023 at $211 and has fallen 93.4% since, to $14 in 2025.

$732in general payments, 2019–2025

Across 32 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$325
  • Sanofi$170
  • GSK$76
  • Intersect ENT, Inc.$50
  • Aerin Medical Inc.$31
  • Inspire Medical Systems, Inc.$27
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$732100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$732 in reported general payments places this provider in the 60th percentile of 42 otolaryngology providers in Maine.

See all otolaryngology providers in Maine

Medicare billing

Part B allowed, 2024
$238,376
Medicare patients
841
Services billed
2,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab12$42,716
Azelastine Hcl195$7,844
Mometasone Furoate88$4,150
Fluticasone Propionate210$3,620
Ipratropium Bromide75$2,744
Pantoprazole Sodium70$1,293
Omeprazole76$1,266
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth14$1,259
Ciprofloxacin Hcl31$638
Montelukast Sodium34$564
Mupirocin57$531
Famotidine60$496
Meclizine Hcl16$290
Hydrochlorothiazide12$288
Nortriptyline Hcl31$267

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Kittery

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →